Date Title & Summary Additional Formats
July 25, 2022
Certara Appoints Rosemary Crane as New Independent Board Member
PRINCETON, N.J. , July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022 . Her appointment brings the company’s board of directors to eleven members.
July 13, 2022
Certara Appoints Eran Broshy as New Independent Board Member
PRINCETON, N.J. , July 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Eran Broshy to its Board of Directors, effective July 11, 2022 . His appointment brings the company’s board of directors to ten members.
July 12, 2022
Certara to Report Second Quarter 2022 Financial Results on August 9th, 2022
PRINCETON, N.J. , July 12, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2022 after the market close on Tuesday, August 9 th , 2022.
June 28, 2022
Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development
Advances lead optimization, first-in-human dose prediction and formulation development PRINCETON, N.J. , June 28, 2022 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Discovery Simulator, a new software designed for scientists
June 21, 2022
Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics
New capabilities enhance clinical predictability for different compounds across more therapeutic areas PRINCETON, N.J. , June 21, 2022 (GLOBE NEWSWIRE) -- Certara , a global leader in biosimulation, today announced the release of new versions of its Immunogenicity (IG), Immuno -oncology (IO) and
May 5, 2022
Certara Reports First Quarter 2022 Financial Results
PRINCETON, N.J. , May 05, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2022. First Quarter Highlights: Revenue was $81.6 million , compared to $66.7 million in the first quarter of
May 3, 2022
Certara to Participate in Upcoming Investor Conferences
PRINCETON, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Bank of America 2022 Healthcare Conference Date and Time:   Tuesday, May 10 at 3:00 p.m.
April 20, 2022
Certara to Report First Quarter 2022 Financial Results on May 5th, 2022
PRINCETON, N.J. , April 20, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2022 after the market close on Thursday, May 5 th , 2022.
March 1, 2022
Certara Reports Fourth Quarter and Full Year 2021 Financial Results
PRINCETON, N.J. , March 01, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2021 and updated guidance for 2022. Fourth Quarter Highlights: Revenue was $75.3 million , compared to
February 23, 2022
U.S. FDA Licenses Certara’s Immunogenicity Simulator
Affirms the advancements of innovative biosimulation technology and its growing impact in R&D PRINCETON, N.J. , Feb. 23, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has licensed Certara’s
Displaying 11 - 20 of 22